Does the media favor PAHC or ENTA?

In the previous week, Phibro Animal Health had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 3 mentions for Phibro Animal Health and 2 mentions for Enanta Pharmaceuticals. Phibro Animal Health's average media sentiment score of 0.50 beat Enanta Pharmaceuticals' score of 0.19 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ENTA or CRON?

In the previous week, Cronos Group had 7 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 9 mentions for Cronos Group and 2 mentions for Enanta Pharmaceuticals. Cronos Group's average media sentiment score of 0.45 beat Enanta Pharmaceuticals' score of 0.19 indicating that Cronos Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cronos Group 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ENTA or AVLN?

In the previous week, Avalyn Pharma had 6 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 8 mentions for Avalyn Pharma and 2 mentions for Enanta Pharmaceuticals. Avalyn Pharma's average media sentiment score of 0.24 beat Enanta Pharmaceuticals' score of 0.19 indicating that Avalyn Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalyn Pharma 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ENTA or LBRX?

In the previous week, LB Pharmaceuticals had 16 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 18 mentions for LB Pharmaceuticals and 2 mentions for Enanta Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.23 beat Enanta Pharmaceuticals' score of 0.19 indicating that LB Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LB Pharmaceuticals 1 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ENTA or CALT?

Enanta Pharmaceuticals presently has a consensus target price of $19.00, suggesting a potential upside of 52.00%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Enanta Pharmaceuticals (ENTA) Competitors

$12.50 +0.40 (+3.31%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$12.56 +0.06 (+0.50%)

As of 10/9/2026 07:57 PM Eastern

Compare

ENTA vs. PAHC, CRON, AVLN, LBRX, and CALT

Should you buy Enanta Pharmaceuticals stock or one of its competitors? Enanta Pharmaceuticals's main competitors and comparable companies include Phibro Animal Health (PAHC), Cronos Group (CRON), Avalyn Pharma (AVLN), LB Pharmaceuticals (LBRX), and Calliditas Therapeutics AB (publ) (CALT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Enanta Pharmaceuticals compare to Phibro Animal Health?

Phibro Animal Health (NASDAQ:PAHC) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Phibro Animal Health has a net margin of 6.57% compared to Enanta Pharmaceuticals' net margin of -96.89%. Phibro Animal Health's return on equity of 37.86% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.57%	37.86%	9.18%
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%

Phibro Animal Health has higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.52B	1.02	$99.72M	$2.44	15.70
Enanta Pharmaceuticals	$65.32M	5.57	-$81.89M	-$2.41	N/A

Phibro Animal Health currently has a consensus price target of $47.67, suggesting a potential upside of 24.46%. Enanta Pharmaceuticals has a consensus price target of $19.00, suggesting a potential upside of 52.00%. Given Enanta Pharmaceuticals' higher probable upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 48.5% of Phibro Animal Health shares are owned by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Phibro Animal Health had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 3 mentions for Phibro Animal Health and 2 mentions for Enanta Pharmaceuticals. Phibro Animal Health's average media sentiment score of 0.50 beat Enanta Pharmaceuticals' score of 0.19 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phibro Animal Health has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

Summary

Phibro Animal Health beats Enanta Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Cronos Group?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Cronos Group (NASDAQ:CRON) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

In the previous week, Cronos Group had 7 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 9 mentions for Cronos Group and 2 mentions for Enanta Pharmaceuticals. Cronos Group's average media sentiment score of 0.45 beat Enanta Pharmaceuticals' score of 0.19 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cronos Group	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enanta Pharmaceuticals has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Cronos Group has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 7.8% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cronos Group has higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.57	-$81.89M	-$2.41	N/A
Cronos Group	$146.59M	8.12	-$9.45M	$0.20	16.15

Cronos Group has a net margin of 39.08% compared to Enanta Pharmaceuticals' net margin of -96.89%. Cronos Group's return on equity of 4.85% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Cronos Group	39.08%	4.85%	4.62%

Enanta Pharmaceuticals currently has a consensus price target of $19.00, suggesting a potential upside of 52.00%. Cronos Group has a consensus price target of $2.30, suggesting a potential downside of 28.79%. Given Enanta Pharmaceuticals' higher probable upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cronos Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Cronos Group beats Enanta Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Avalyn Pharma?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Enanta Pharmaceuticals currently has a consensus target price of $19.00, suggesting a potential upside of 52.00%. Avalyn Pharma has a consensus target price of $60.00, suggesting a potential upside of 132.92%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Avalyn Pharma is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Avalyn Pharma has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -96.89%. Avalyn Pharma's return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Avalyn Pharma	N/A	N/A	N/A

Avalyn Pharma has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.57	-$81.89M	-$2.41	N/A
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A

In the previous week, Avalyn Pharma had 6 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 8 mentions for Avalyn Pharma and 2 mentions for Enanta Pharmaceuticals. Avalyn Pharma's average media sentiment score of 0.24 beat Enanta Pharmaceuticals' score of 0.19 indicating that Avalyn Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalyn Pharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Avalyn Pharma beats Enanta Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to LB Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and LB Pharmaceuticals (NASDAQ:LBRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, LB Pharmaceuticals had 16 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 18 mentions for LB Pharmaceuticals and 2 mentions for Enanta Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.23 beat Enanta Pharmaceuticals' score of 0.19 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LB Pharmaceuticals	1 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

LB Pharmaceuticals has lower revenue, but higher earnings than Enanta Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.57	-$81.89M	-$2.41	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A

Enanta Pharmaceuticals currently has a consensus price target of $19.00, suggesting a potential upside of 52.00%. LB Pharmaceuticals has a consensus price target of $57.40, suggesting a potential upside of 54.22%. Given LB Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe LB Pharmaceuticals is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

LB Pharmaceuticals has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -96.89%. LB Pharmaceuticals' return on equity of -25.92% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
LB Pharmaceuticals	N/A	-25.92%	-24.68%

Summary

LB Pharmaceuticals beats Enanta Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Enanta Pharmaceuticals' net margin of -96.89%. Enanta Pharmaceuticals' return on equity of -61.84% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Enanta Pharmaceuticals. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.57	-$81.89M	-$2.41	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Enanta Pharmaceuticals has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

In the previous week, Enanta Pharmaceuticals had 2 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for Enanta Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Enanta Pharmaceuticals' average media sentiment score of 0.19 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Neutral
Calliditas Therapeutics AB (publ)	Neutral

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Enanta Pharmaceuticals presently has a consensus target price of $19.00, suggesting a potential upside of 52.00%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Enanta Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 11 of the 16 factors compared between the two stocks.

Get Enanta Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTA vs. The Competition

Export

Metric	Enanta Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$352.42M	$12.35B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-5.19	797.58	274.15	26.16
Price / Sales	5.57	757.89	590.50	94.68
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	4.13	10.71	11.21	6.34
Net Income	-$81.89M	$2.84B	$3.50B	$381.90M
7 Day Performance	-3.55%	-0.93%	-0.90%	-1.41%
1 Month Performance	-1.57%	-4.91%	-4.44%	-3.48%
1 Year Performance	13.43%	-4.13%	6.96%	1.16%

Enanta Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTA Enanta Pharmaceuticals	2.228 of 5 stars	$12.50 +3.3%	$19.00 +52.0%	+9.1%	$352.42M	$65.32M	N/A	120
PAHC Phibro Animal Health	4.5859 of 5 stars	$35.45 -0.7%	$47.67 +34.5%	+3.0%	$1.45B	$1.52B	14.53	2,605	News Coverage
CRON Cronos Group	1.693 of 5 stars	$3.38 -0.9%	$2.30 -32.0%	+19.2%	$1.26B	$146.59M	16.90	610	News Coverage Analyst Upgrade
AVLN Avalyn Pharma	2.8468 of 5 stars	$27.10 -4.3%	$60.00 +121.4%	N/A	$1.26B	N/A	N/A	55
LBRX LB Pharmaceuticals	2.5343 of 5 stars	$37.28 -1.6%	$49.63 +33.1%	+138.0%	$1.22B	N/A	N/A	27	Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTA) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. PAHC, CRON, AVLN, LBRX, and CALT

How does Enanta Pharmaceuticals compare to Phibro Animal Health?

Summary

How does Enanta Pharmaceuticals compare to Cronos Group?

Summary

How does Enanta Pharmaceuticals compare to Avalyn Pharma?

Summary

How does Enanta Pharmaceuticals compare to LB Pharmaceuticals?

Summary

How does Enanta Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. PAHC, CRON, AVLN, LBRX, and CALT

How does Enanta Pharmaceuticals compare to Phibro Animal Health?

Is PAHC or ENTA more profitable?

Which has preferable valuation & earnings, PAHC or ENTA?

Do analysts recommend PAHC or ENTA?

Do institutionals & insiders have more ownership in PAHC or ENTA?

Does the media favor PAHC or ENTA?

Which has more risk and volatility, PAHC or ENTA?

Summary

How does Enanta Pharmaceuticals compare to Cronos Group?

Does the media prefer ENTA or CRON?

Which has more risk & volatility, ENTA or CRON?

Do insiders & institutionals hold more shares of ENTA or CRON?

Which has preferable earnings and valuation, ENTA or CRON?

Is ENTA or CRON more profitable?

Do analysts recommend ENTA or CRON?

Summary

How does Enanta Pharmaceuticals compare to Avalyn Pharma?

Do insiders and institutionals have more ownership in ENTA or AVLN?

Do analysts recommend ENTA or AVLN?

Is ENTA or AVLN more profitable?

Which has stronger valuation & earnings, ENTA or AVLN?

Does the media prefer ENTA or AVLN?

Summary

How does Enanta Pharmaceuticals compare to LB Pharmaceuticals?

Do institutionals and insiders have more ownership in ENTA or LBRX?

Does the media refer more to ENTA or LBRX?

Which has preferable valuation and earnings, ENTA or LBRX?

Do analysts recommend ENTA or LBRX?

Is ENTA or LBRX more profitable?

Summary

How does Enanta Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Is ENTA or CALT more profitable?

Which has better earnings & valuation, ENTA or CALT?

Which has more risk and volatility, ENTA or CALT?

Does the media prefer ENTA or CALT?

Do insiders and institutionals have more ownership in ENTA or CALT?

Do analysts rate ENTA or CALT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools